<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03706274</url>
  </required_header>
  <id_info>
    <org_study_id>CTMX-M-188-001</org_study_id>
    <nct_id>NCT03706274</nct_id>
  </id_info>
  <brief_title>PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Ranging Study of the PD-1 Probody Therapeutic CX-188 in Adults With Recurrent or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytomX Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytomX Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-human study of CX-188 is to characterize the safety,
      tolerability, pharmacokinetics (PK), and antitumor activity of CX-188 in adult subjects with
      metastatic or advanced unresectable solid tumors that progressed on standard therapy:
      PROCLAIM: PRObody Clinical Assessment in Man CX-188 clinical trial 001
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-188 as a monotherapy</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects experiencing anti-cancer activity (ORR) at various dose levels when given CX-188 as monotherapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>CX-188 Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-188 Alternative Dosing Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX-188</intervention_name>
    <description>CX-188</description>
    <arm_group_label>CX-188 Alternative Dosing Schedule</arm_group_label>
    <arm_group_label>CX-188 Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically confirmed diagnosis of metastatic or advanced unresectable solid tumors
             that progressed on standard therapy

          2. agreement to provide mandatory archival tumor or fresh biopsy before they can be
             considered for inclusion in the study 3. At least 18 years old

        Exclusion Criteria:

          1. Prior therapy with a chimeric antigen receptor (CAR) T-cell containing regimen.

          2. History of severe allergic or anaphylactic reactions to human monoclonal antibody
             therapy or known hypersensitivity to any Probody therapeutic

          3. Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome
             (AIDS)-related illness, chronic hepatitis B or C

          4. History of or current active autoimmune diseases

          5. History of syndrome or medical condition(s) that requires systemic steroids (&gt; 10 mg
             daily prednisone equivalents) or immunosuppressive medications

          6. History of allogeneic tissue/solid organ transplant, prior stem cell or bone marrow
             transplant

          7. Chemotherapy, biochemotherapy, radiation or immunotherapy or any investigational
             treatment within 30 days prior to receiving any study drug

          8. Major surgery (requiring general anesthesia) within 3 months or minor surgery
             (excluding biopsies conducted with local/topical anesthesia) or gamma knife treatment
             within 14 days (with adequate healing) of administration of any study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yifah Yaron, MD</last_name>
    <role>Study Director</role>
    <affiliation>CytomX Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Albert</last_name>
    <phone>650-528-2929</phone>
    <email>clinicaltrials@cytomx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>July 26, 2019</last_update_submitted>
  <last_update_submitted_qc>July 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

